Share-based Payment Arrangement, Expense of OnKure Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
OnKure Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • OnKure Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,961,000, a 3745% increase year-over-year.
  • OnKure Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $11,147,000.
  • OnKure Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4,530,000, a 2176% increase from 2023.
  • OnKure Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $199,000, a 95% decline from 2022.
  • OnKure Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,320,000, a 11% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

OnKure Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $11,147,000 $2,961,000 +$2,884,000 +3745% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $8,263,000 $2,908,000 +$1,095,000 +60% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $7,168,000 $2,745,000 +$2,638,000 +2465% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $4,530,000 $2,533,000 +$6,127,000 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
Q3 2024 $1,597,000 $77,000 -$1,352,000 -95% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $245,000 $1,813,000 +$606,000 +50% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $851,000 $107,000 -$1,050,000 -91% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $199,000 $3,594,000 -$4,811,000 -395% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $5,010,000 $1,429,000 +$439,000 +44% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $4,571,000 $1,207,000 +$201,000 +20% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $4,370,000 $1,157,000 +$50,000 +4.5% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $4,320,000 $1,217,000 -$204,000 -14% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $4,524,000 $990,000 -$155,000 -14% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $4,679,000 $1,006,000 +$152,000 +18% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $4,527,000 $1,107,000 +$636,000 +135% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $3,891,000 $1,421,000 +$1,292,000 +1002% 01 Oct 2021 31 Dec 2021 10-K 27 Mar 2023 2022 FY
Q3 2021 $2,599,000 $1,145,000 +$1,061,000 +1263% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $1,538,000 $854,000 +$766,000 +870% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $772,000 $471,000 +$379,000 +412% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $393,000 $129,000 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
Q3 2020 $84,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $88,000 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $92,000 01 Jan 2020 31 Mar 2020 10-Q 20 May 2021 2021 Q1

OnKure Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,530,000 +$4,331,000 +2176% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
2023 $199,000 -$4,121,000 -95% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $4,320,000 +$429,000 +11% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $3,891,000 +$3,498,000 +890% 01 Jan 2021 31 Dec 2021 10-K 27 Mar 2023 2022 FY
2020 $393,000 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.